FrancophonIA/ELRC3.0 huggingface dataset:
English: Activating mutations in JAK2 (V617F or exon 12) are found in >95% of PV patients.
Estonian: >95%-l PV patsientidest esinevad aktiveerivad mutatsioonid JAK2's (V617F's või ekson 12's).
English: Thrombocytopenia was generally reversible with dose reduction or dose interruption.
Estonian: Trombotsütopeenia oli enamasti annuse vähendamisel või ravi katkestamisel mööduv.
English: The starting dose of Jakavi was based on platelet count.
Estonian: Jakavi algannus põhines trombotsüütide arvul.
English: Jakavi can relieve the symptoms, reduce spleen size and the volume of red blood cells produced in patients with polycythaemia vera by selectively blocking enzymes called Janus Associated Kinases (JAK1 and JAK2), thus potentially reducing the risk of serious blood or vascular complications.
Estonian: Blokeerides selektiivselt Janus kinaasi nimelisi ensüüme (JAK1 ja JAK2), võib Jakavi polycytaemia vera patsientidel sümptome leevendada, vähendada põrna mahtu ja vere punaliblede tootmist ning seega potentsiaalselt vähendada tõsiste vere ja veresoontega seotud tüsistuste riski.
English: Parent compound is the predominant entity in human plasma, representing approximately 60% of the drug-related material in circulation.
Estonian: Inimese vereplasmas esineb ruksolitiniib peamiselt muutumatul kujul, moodustades veres tsirkuleerivatest ravimiga seotud ühenditest ligikaudu 60%.
English: In this arm, 83% of patients were still on treatment at the time of the week 80 data cut-off. Of patients who achieved a primary response at week 32, 80% maintained their response for at least 48 weeks after the initial response.
Estonian: 80%-l patsientidest, kes saavutasid 32. nädal esmase ravivastuse, püsis ravivastus täiendavad 48 nädalat pärast esmast ravivastuse saavutamist.
English: In these clinical studies, discontinuation due to adverse events, regardless of causality, was observed in 11.3% of patients.
Estonian: Nendes kliinilistes uuringutes katkestas 11,3% patsientidest ravi kõrvaltoimete tõttu, põhjuslikku seost arvestama.
English: There is no known antidote for overdoses with Jakavi.
Estonian: Antidoot Jakavi üleannustamise raviks puudub.
English: In the phase 3 clinical studies in MF, in patients who developed grade 3 or 4 thrombocytopenia, the median time to onset was approximately 8 weeks.
Estonian: MF'i III faasi kliinilistes uuringutes oli 3. või 4. raskusastme trombotsütopeenia tekke mediaanaeg ligikaudu 8 nädalat.
English: Pharmacokinetic/pharmacodynamic simulations based on available data in this population suggest that the starting dose for MF patients with ESRD on haemodialysis is a single dose of 15-20 mg or two doses of 10 mg given 12 hours apart, to be administered post-dialysis and only on the day of haemodialysis.
Estonian: Olemasolevatel andmetel põhinevad farmakokineetilised/farmakodünaamilised simulatsioonid antud patsientide populatsioonis näitavad, et algannus hemodialüüsravi saavatel lõppstaadiumis neeruhaigusega MF'i patsientidel on üksikannusena 15...20 mg või kaks 10 mg annust 12-tunnise vahega, mis tuleks manustada peale dialüüsi ja ainult hemodialüüsi päeval.
English: If Jakavi is to be co-administered with strong CYP3A4 inhibitors or dual inhibitors of CYP3A4 and CYP2C9 enzymes (e.g. fluconazole), the unit dose of Jakavi should be reduced by approximately 50%, to be administered twice daily (for monitoring frequency see sections 4.2 and 4.5).
Estonian: Kui Jakavi't kasutatakse koos tugevatoimeliste CYP3A4 inhibiitoritega või CYP3A4 ja CYP2C9 ensüümide ühiste inhibiitoritega (nt flukonasooliga), tuleb Jakavi üksikannuseid kaks korda ööpäevas manustamise korral vähendada ligikaudu 50% võrra (jälgimise sageduse kohta vt lõigud 4.2 ja 4.5).
English: Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anaemia and thrombocytopenia.
Estonian: Soovitatavatest annustest suuremate annuste korduval manustamisel on suurem oht müelosupressiooni tekkeks (leukopeenia, aneemia ja trombotsütopeenia).
English: The concurrent use of haematopoietic growth factors and ruxolitinib has not been studied.
Estonian: Hematopoeetiliste kasvufaktorite ja ruksolitiniibi samaaegset kasutamist ei ole uuritud.
English: Jakavi 5 mg tablets Jakavi 10 mg tablets Jakavi 15 mg tablets Jakavi 20 mg tablets
Estonian: Jakavi 5 mg tabletid Jakavi 10 mg tabletid Jakavi 15 mg tabletid Jakavi 20 mg tabletid
English: In COMFORT-I, after a median follow-up of 61.7 months, the death rate in patients randomised to the ruxolitinib arm was 44.5% (69 of 155 patients) versus 53.2% (82 of 154) in patients randomised to placebo.
Estonian: COMFORT-I uuringus, pärast jälgimisperioodi mediaankestusega 61,7 kuud, oli ruksolitiniibi rühma randomiseeritud patsientide suremus 44,5% (69 patsienti 155-st) võrreldes 53,2%-ga (82 patsienti 154-st) platseeborühmas.
English: The proportion of patients achieving a complete haematological remission was 23.6% on Jakavi compared to 8.0% on BAT (p=0.0013) and the proportion of patients achieving a durable primary response at week 48 was 20% on Jakavi and 0.9% on BAT (p<0.0001).
Estonian: Täieliku hemotoloogilise remissiooni saavutanud patsientide osakaal oli Jakavi rühmas 23,6% võrreldes 8,0%-ga BAT'i rühmas (p= 0,0013) ning 48. nädalaks kestma jäänud esmase tulemusnäitaja saavutas Jakavi rühmas 20% võrreldes 0,9%-ga BAT'i rühmas (p<0,0001).
English: Cellulose, microcrystalline Magnesium stearate Silica, colloidal anhydrous Sodium starch glycolate (Type A) Povidone K30
Estonian: Kolloidne veevaba ränidioksiid Naatriumtärklisglükolaat (A tüüpi) Povidoon K30
English: c grade 3 (<1,000 - 500/mm
Estonian: 3. raskusaste (<1 000…500/mm
English: If you have questions about how long to take Jakavi, talk to your doctor or pharmacist.
Estonian: Kui teil on küsimusi Jakavi kasutamise kestuse osas, siis rääkige oma arsti või apteekriga.
English: In the randomised period of the pivotal study in PV patients, neutropenia was reported in three patients (1.6%) of which one patient developed CTCAE grade 4 neutropenia.
Estonian: PV patsientidel teatati olulise tähtsusega uuringute randomiseerimise perioodis kolmest neutropeenia juhust (1,6%), nendest ühel juhul tekkis patsiendil CTCAE 4. raskusastme neutropeenia.
English: Table 2 Percentage of patients with ≥35% reduction from baseline in spleen volume at week 24 in COMFORT-I and at week 48 in COMFORT-II (ITT)
Estonian: Tabel 2 Patsientide osakaal, kellel saavutati 24. nädalal (COMFORT-I) ja 48. nädalal (COMFORT-II) põrna mahu ≥ 35% vähenemine võrreldes algtasemega (ravikavatsuslik populatsioon)
English: Discontinuation due to adverse events, regardless of causality, was observed in 2.2% of patients.
Estonian: Põhjuslikku seost arvestamata katkestas kõrvaltoimete tõttu ravi 2,2% patsientidest.
English: Gastrointestinal bleeding was reported in 5.0% of patients exposed to ruxolitinib compared to 3.1% exposed to reference treatments.
Estonian: Seedetrakti verejooksu täheldati 5,0% ruksolitiniibi kasutanud patsientidel võrrelduna 3,1% võrdlusravi saanud patsientidega.
English: c grade 4 (<500/mm
Estonian: 4. raskusaste (<500/mm
English: Subsequent doses (single dose of 20 mg or two doses of 10 mg given 12 hours apart in MF patients; single dose of 10 mg or two doses of 5 mg given 12 hours apart in PV patients) should be administered only on haemodialysis days following each dialysis session.
Estonian: Edasised annused (MF'i patsientidel üksikannusena 20 mg või kaks 10 mg annust 12-tunnise vahega; PV patsientidel üksikannusena 10 mg või kaks 5 mg annust 12-tunnise vahega) manustatakse ainult dialüüsi päevadel pärast dialüüsiprotseduuri.
English: There have been cases of patients discontinuing Jakavi who sustained more severe events, particularly in the presence of acute intercurrent illness.
Estonian: On teateid patsientidest, kellel pärast Jakavi kasutamise lõpetamist on sümptomid taastunud raskemal kujul kui enne ravi alustamist, eriti mõne ägeda haiguse kaasnemisel.
English: - The recommended starting dose in polycythaemia vera is 10 mg twice daily.
Estonian: - Polycytaemia vera korral on soovitatav algannus 10 mg kaks korda ööpäevas.
English: In COMFORT-I, after a median follow-up of 34.3 months, the death rate in patients randomised to the ruxolitinib arm was 27.1% versus 35.1% in patients randomised to placebo; HR 0.687; 95% CI 0.459-1.029; p=0.0668.
Estonian: COMFORT-I uuringus, pärast jälgimisperioodi mediaankestusega 34,3 kuud, oli ruksolitiniibi rühma randomiseeritud patsientide suremus 27,1% võrreldes 35,1%-ga platseeborühmas; HR 0,687; 95% CI 0,459...1,029; p= 0,0668.
English: In phase 3 clinical studies in MF, median time to onset of first CTCAE grade 2 or higher anaemia was 1.5 months.
Estonian: MF'i III faasi kliinilistes uuringutes oli CTCAE 2. raskusastme või raskema aneemia tekke mediaanaeg 1,5 kuud.
English: The key secondary endpoint defined as the proportion of patients achieving complete haematological remission at week 28 was also met (23.0% in the Jakavi arm versus 5.3% in the BAT arm).
Estonian: Olulise tähtsusega teisene tulemusnäitaja oli patsientide osakaal, kes saavutasid 28. nädalaks täieliku hematoloogilise remissiooni (23,0% Jakavi rühmas versus 5,3% parima saadaoleva ravi rühmas).
English: Ruxolitinib decreased foetal weight and increased post-implantation loss in animal studies.
Estonian: Ruksolitiniib vähendas loomuuringutes loodete kehakaalu ja suurendas implantatsioonijärgset hukkumist.
English: The primary efficacy endpoint was proportion of patients achieving ≥35% reduction from baseline in spleen volume at week 48 as measured by MRI or CT.
Estonian: Esmane tulemusnäitaja oli patsientide osakaal, kellel saavutati MRT või KT alusel hinnates 48. nädalal põrna mahu ≥ 35% vähenemine võrreldes algtasemega.
English: Jakavi contains lactose.
Estonian: Jakavi sisaldab laktoosi.
English: Two randomised phase 3 studies (COMFORT-I and COMFORT-II) were conducted in patients with MF (primary MF, post-polycythaemia vera MF or post-essential thrombocythaemia MF).
Estonian: MF'iga patsientidel (primaarne MF, polycytaemia vera järgne MF või essentsiaalse trombotsüteemia järgne MF) on läbi viidud kaks III faasi randomiseeritud uuringut (COMFORT-I ja COMFORT-II).
English: What Jakavi contains - The active substance of Jakavi is ruxolitinib.
Estonian: Mida Jakavi sisaldab - Jakavi toimeaine on ruksolitiniib.
English: The primary composite endpoint was the proportion of patients achieving both an absence of phlebotomy eligibility (HCT control) and a ≥35% reduction in spleen volume from baseline at week 32.
Estonian: Esmane liittulemusnäitaja oli patsientide osakaal, kellele esiteks puudus vajadus teha flebotoomiat (hematokriti [HCT] kontroll), ja teiseks, kelle põrna maht oli 32. nädalaks vähenenud ≥35% võrreldes algtasemega.
English: Excipient with known effect Each tablet contains 285.80 mg lactose monohydrate.
Estonian: Teadaolevat toimet omav abiaine: Üks tablett sisaldab 285,80 mg laktoosmonohüdraati.
English: Excipient with known effect Each tablet contains 71.45 mg lactose monohydrate.
Estonian: Teadaolevat toimet omav abiaine: Üks tablett sisaldab 71,45 mg laktoosmonohüdraati.
English: In patients with any hepatic impairment the recommended starting dose based on platelet count should be reduced by approximately 50% to be administered twice daily.
Estonian: Maksakahjustusega patsientidel tuleb trombotsüütide arvul põhinevat soovitatavat algannust vähendada ligikaudu 50% võrra manustatuna kaks korda ööpäevas.
English: 10 g/litre below baseline after 8 to 12 weeks of therapy and then gradually recovered to reach a new steady state that was approximately 5 g/litre below baseline.
Estonian: Ruksolitiniibiga ravitud patsientidel saabus vere hemoglobiinisisalduse vähenemise nadiir (ligikaudu 10 g/l madalam võrreldes algtasemega) pärast 8…12-nädalast ravi ning taastus seejärel järkjärgult uuel tasemel, mis oli ligikaudu 5 g/l võrra madalam kui algtase.
English: Haemodialysis is not expected to enhance the elimination of ruxolitinib.
Estonian: Hemodialüüs ei kiirenda ilmselt ruksolitiniibi eemaldamist organismist.
English: Therapeutic drug monitoring (TDM) or clinical monitoring of the affected substance is advised.
Estonian: Soovitatav on nende ravimite plasma kontsentratsiooni määramine või kliiniline jälgimine.
English: Appropriate supportive treatment should be given.
Estonian: Üleannustamise ravi on vajaduse korral toetav.
English: In the phase 3 clinical studies in MF, in patients who developed grade 3 or 4 neutropenia, the median time to onset was 12 weeks.
Estonian: MF'i III faasi kliinilistes uuringutes oli 3. või 4. raskusastme neutropeenia tekke mediaanaeg 12 nädalat.
English: Positive (N=121) n (%)
Estonian: Positiivne (N=121) n (%)
English: Non-melanoma skin cancers (NMSCs), including basal cell, squamous cell, and Merkel cell carcinoma, have been reported in patients treated with ruxolitinib.
Estonian: Ruksolitiniibravi saanud patsientidel on teatatud mitte-melanoom nahavähkidest (non-melanoma skin cancer, NMSC), sealhulgas basaalrakulisest, lamerakulisest ja merkelirakk-kartsinoomist.
English: 3, with the goal of avoiding dose interruptions for thrombocytopenia.
Estonian: 3, tuleb kaaluda annuse vähendamist, et vältida ravi katkestamisi trombotsütopeenia tõttu.
English: Lipid monitoring and treatment of dyslipidaemia according to clinical guidelines is recommended.
Estonian: Soovitatav on jälgida lipiidide sisaldust veres ning vastavalt ravijuhistele ravida düslipideemiat.
English: It may be necessary to treat your infection before starting Jakavi.
Estonian: Enne ravi Jakavi'ga võib olla vajalik selle ravi.
English: Dose modifications or interruption for patients developing anaemia may also be considered.
Estonian: Aneemiaga patsientidel tuleb samuti kaaluda annuse muutmist või ravi lõpetamist.
English: c grade 4 (<25,000/mm
Estonian: 4. raskusaste (<25 000/mm
English: Doses were then adjusted in individual patients based on tolerability and efficacy with a maximum dose of 25 mg twice daily.
Estonian: Vastavalt taluvusele ja efektiivsusele kohandati individuaalselt patsientide Jakavi annust maksimaalse annuseni 25 mg kaks korda ööpäevas.
English: Jakavi 5 mg tablets Jakavi 10 mg tablets Jakavi 15 mg tablets Jakavi 20 mg tablets ruxolitinib
Estonian: Jakavi 5 mg tabletid Jakavi 10 mg tabletid Jakavi 15 mg tabletid Jakavi 20 mg tabletid ruksolitiniib (Ruxolitinibum)
English: The half-life was prolonged from 3.7 to 6.0 hours with concurrent ketoconazole administration.
Estonian: Samaaegne ketokonasooli manustamine pikendas ruksolitiniibi poolväärtusaega 3,7 tunnilt 6,0 tunnini.
English: Dose reductions should be considered if the platelet count decreases below 100,000/mm
Estonian: Kui trombotsüütide arv langeb alla 100 000/mm
English: When administering ruxolitinib with strong CYP3A4 inhibitors the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily.
Estonian: Kui ruksolitiniibi kasutatakse koos tugevatoimeliste CYP3A4 inhibiitoritega, tuleb ruksolitiniibi üksikannuseid kaks korda ööpäevas manustamise korral vähendada ligikaudu 50% võrra.
English: The recommended starting dose for PV patients with severe renal impairment is 5 mg twice daily.
Estonian: PV korral on raske neerukahjustusega patsientidel soovitatav algannus 5 mg kaks korda ööpäevas.
English: It is possible that in the individual patient, an increase of the ruxolitinib dose is needed when initiating treatment with a strong enzyme inducer.
Estonian: Kui alustatakse ravi ensüümi tugeva indutseerijaga, võib mõnedel patsientidel olla vajalik ruksolitiniibi annuse tõstmine.
English: Hepatitis B viral load (HBV-DNA titre) increases, with and without associated elevations in alanine aminotransferase and aspartate aminotransferase, have been reported in patients with chronic HBV infections taking Jakavi.
Estonian: Jakavi't kasutanud kroonilise HBV infektsiooniga patsientidel on teatatud B-hepatiidi viiruskoormuse (HBV DNA sisalduse) suurenemisest koos kaasneva alaniinaminotransferaasi ja aspartaataminotransferaasi tõusuga ja ilma.
English: No intracranial bleeding or gastrointestinal haemorrhage events were reported in patients receiving ruxolitinib.
Estonian: Ruksolitiniibi patsientidel ei teatatud intrakraniaalse ega seedetrakti verejooksu juhtudest.
English: A significantly higher proportion of patients in the Jakavi group achieved ≥35% reduction from baseline in spleen volume (Table 2) regardless of the presence or absence of the JAK2V617F mutation or the disease subtype (primary MF, post-polycythaemia vera MF, post-essential thrombocythaemia MF).
Estonian: Sõltumata JAK2V617F mutatsiooni esinemisest või haiguse alamtüübist (primaarne MF, polycytaemia vera järgne MF või essentsiaalse trombotsüteemia järgne MF) saavutati põrna mahu ≥ 35% vähenemine (tabel 2) võrreldes algtasemega oluliselt suuremal osal patsientidest Jakavi rühmas.
English: Hepatobiliary disorders Raised alanine aminotransferase b
Estonian: Maksa ja sapiteede häired Alaniinaminotransferaasi sisalduse suurenemine b
English: The concomitant use of cytoreductive therapies and ruxolitinib has not been studied.
Estonian: Tsütoredutseeriva ravi ja ruksolitiniibi koostoimet ei ole uuritud.
English: Excipient with known effect Each tablet contains 142.90 mg lactose monohydrate.
Estonian: Teadaolevat toimet omav abiaine: Üks tablett sisaldab 142,90 mg laktoosmonohüdraati.
English: The recommended starting dose for PV patients with ESRD on haemodialysis is a single dose of 10 mg or two doses of 5 mg given 12 hours apart, to be administered post-dialysis and only on the day of haemodialysis.
Estonian: Soovitatav algannus hemodialüüsravi saavatel lõppstaadiumis neeruhaigusega PV patsientidel on üksikannusena 10 mg või kaks 5 mg annust 12-tunnise vahega, mis tuleks manustada peale dialüüsi ja ainult hemodialüüsi päeval.
English: Positive (N=110) n (%)
Estonian: Positiivne (N=110) n (%)
English: Dose adjustment with concomitant strong CYP3A4 inhibitors or fluconazole When ruxolitinib is administered with strong CYP3A4 inhibitors or dual inhibitors of CYP2C9 and CYP3A4 enzymes (e.g. fluconazole) the unit dose of ruxolitinib should be reduced by approximately 50%, to be administered twice daily (see section 4.5).
Estonian: Kui ruksolitiniibi kasutatakse koos tugevatoimeliste CYP3A4 inhibiitorite või CYP2C9 ja CYP3A4 ensüümide ühiste inhibiitoritega (nt flukonasooliga), tuleb ruksolitiniibi üksikannuseid kaks korda ööpäevas manustamise korral vähendada ligikaudu 50% võrra (vt lõik 4.5).
English: Increased systolic blood pressure
Estonian: Süstoolse vererõhu tõus
English: Positive (N=49) n (%)
Estonian: Positiivne (N=49) n (%)
English: Talk to your doctor or pharmacist during your treatment with Jakavi - if you experience unexpected bruising and/or bleeding, unusual tiredness, shortness of breath during exercise or at rest, unusually pale skin, or frequent infections (these are signs of blood disorders).
Estonian: (sage); - teadmata põhjusega verevalumid ja/või veritsus, ebatavaline väsimus, hingamisraskused liikumise või puhkamise ajal, ebatavaliselt kahvatu nahk või sagedased infektsioonid
English: Positive (N=113) n (%)
Estonian: Positiivne (N=113) n (%)
English: Fractures and early termination of rats were observed at doses ≥30 mg/kg/day when treatment was started on postnatal day 7.
Estonian: Annustes ≥30 mg/kg/ööpäevas, kui ravi alustati 7 päeva vanustel rottidel, täheldati murdude teket ja varast hukkumist.
English: Jakavi 20 mg tablets
Estonian: Jakavi 20 mg tabletid
English: Jakavi is used to treat adult patients with an enlarged spleen or with symptoms related to myelofibrosis, a rare form of blood cancer.
Estonian: Jakavi't kasutatakse põrna suurenemise või müelofibroosiga seotud sümptomitega täiskasvanud patsientide raviks.
English: Vascular disorders Hypertensiona
Estonian: Vaskulaarsed häired Hüpertensioon a
English: Therefore, it is not anticipated that the contraceptive efficacy of this combination will be compromised by co-administration of ruxolitinib.
Estonian: Seega ei ole oodata sellise kombinatsiooni rasestumisvastase toime langust samaaegsel kasutamisel ruksolitiniibiga.
English: There was a 33% reduction in risk of death in the ruxolitinib arm compared to the BAT arm (HR 0.67; 95% CI 0.44-1.02; p=0.062).
Estonian: Võrreldes parima olemasoleva ravi rühmaga oli ruksolitiniibi rühmas surma risk 33% väiksem (HR 0,67; 95% CI 0,44…1,02; p=0,062).
English: In the pups, decreased mean initial body weights and short period of decreased mean body weight gain were observed.
Estonian: Järglastel on leitud keskmise vahetu sünnijärgse kehakaalu vähenemine ja lühiaegne keskmise kehakaalu kasvu vähenemine.
English: Negative (N=35) n (%)
Estonian: Negatiivne (N=35) n (%)
English: OUTER CARTON OF MULTIPACK
Estonian: HULGIPAKENDI VÄLISKARP
English: Other interactions to be considered affecting ruxolitinib
Estonian: Muud ruksolitiniibi mõjutavad arvestamist vajavad koostoimed
English: Excipient with known effect Each tablet contains 214.35 mg lactose monohydrate.
Estonian: Teadaolevat toimet omav abiaine: Üks tablett sisaldab 217,35 mg laktoosmonohüdraati.
English: Dose modifications
Estonian: Annuse muutmine
English: Jakavi 20 mg tablets Each tablet contains 20 mg ruxolitinib (as phosphate).
Estonian: Jakavi 20 mg tabletid Üks tablett sisaldab 20 mg ruksolitiniibi (Ruxolitinibum) (fosfaadina).
English: Discontinuation of treatment because of thrombocytopenia occurred in 0.7% of patients receiving ruxolitinib and 0.9%
Estonian: Trombotsütopeenia tõttu katkestati ravi 0,7% patsientidest ruksolitiniibi rühmas ning 0,9% patsiendest kontrollrühmas.
English: The starting dose of Jakavi should be reduced by approximately 50% in patients with hepatic impairment.
Estonian: Maksakahjustusega patsientidel tuleb algannust vähendada ligikaudu 50% võrra.
English: Serious bacterial, mycobacterial, fungal, viral and other opportunistic infections have occurred in patients treated with Jakavi.
Estonian: Jakavi'ga ravitud patsientidel on esinenud tõsiseid bakteriaalseid, mükobakteriaalseid, seen- ja viirusinfektsioone.
English: The recommended starting dose of ruxolitinib in MF is 15 mg twice daily for patients with a platelet count between 100,000/mm and 200,000/mm and 20 mg twice daily for patients with a platelet count of >200,000/mm 3.
Estonian: 3…200 000/mm ruksolitiniibi soovitatav algannus 15 mg kaks korda ööpäevas, ning patsientidel, kelle trombotsüütide arv on > 200 000/mm
English: The maximum dose of ruxolitinib is 25 mg twice daily.
Estonian: Ruksolitiniibi maksimaalne annus on 25 mg kaks korda ööpäevas.
English: - Each 20 mg Jakavi tablet contains 20 mg of ruxolitinib.
Estonian: - Üks 20 mg Jakavi tablett sisaldab 20 mg ruksolitiniibi.
English: Jakavi 10 mg tablets
Estonian: Jakavi 10 mg tabletid
English: Negative (N=27) n (%)
Estonian: Negatiivne (N=27) n (%)
English: Jakavi 10 mg tablets EU/1/12/773/014-016
Estonian: Jakavi 10 mg tabletid EU/1/12/773/014-016
English: Negative (N=20) n (%)
Estonian: Negatiivne (N=20) n (%)
English: Jakavi 5 mg tablets EU/1/12/773/004-006
Estonian: Jakavi 5 mg tabletid EU/1/12/773/004-006
English: Negative (N=40) n (%)
Estonian: Negatiivne (N=40) n (%)
English: Jakavi 20 mg tablets EU/1/12/773/010-012
Estonian: Jakavi 20 mg tabletid EU/1/12/773/010-012
English: Jakavi 5 mg tablets Each tablet contains 5 mg ruxolitinib (as phosphate).
Estonian: Jakavi 5 mg tabletid Üks tablett sisaldab 5 mg ruksolitiniibi (Ruxolitinibum) (fosfaadina).
English: Jakavi 5 mg tablets
Estonian: Jakavi 5 mg tabletid
English: Jakavi 15 mg tablets EU/1/12/773/007-009
Estonian: Jakavi 15 mg tabletid EU/1/12/773/007-009
English: Nervous system disorders Dizziness a
Estonian: Närvisüsteemi häired Pearinglus a
English: Effects of ruxolitinib on other medicinal products
Estonian: Ruksolitiniibi toime teistele ravimitele
English: study and 2.7% of patients receiving best available therapy in RESPONSE 2 study.
Estonian: Verevalumitest teatati 10,3%-l ruksolitiniibi patsientidest ja 8,1%-l patsientidest, kes said parimat olemasolevat ravi RESPONSE uuringus, ning 2,7%-l patsientidest, kes said parimat olemasolevat ravi RESPONSE 2 uuringus.
English: Jakavi 15 mg tablets
Estonian: Jakavi 15 mg tabletid